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INTRODUCTION 
The treatment of locally advanced rectal cancer involves pre-operative chemoradiotherapy (CRT) 
followed by surgery after an interval of approximately 6 weeks. The response to CRT is assessed 
using the histopathological tumour regression grade (TRG), following surgery.  
High resolution T2W MRI is excellent in determining the extent of the tumour. It is also used 
in reassessing the tumour after pre-operative CRT. Tumour regression and downstaging is an 
important prognostic factor in local tumour recurrence rate and 5-year survival. However, 
when it comes to re-staging after CRT there is difficulty in recognizing residual tumour in 
areas of radiation induced fibrosis, desmoplasia and mucinous change. 
Prediction of tumour response before onset of treatment could have considerable clinical benefit, 
especially in prognostication and tailoring of therapy.  
Because of its promise in cancer imaging, we have looked at the potential role of DWI in 
carcinoma rectum. The hypothesis is that DWI can be more valuable than standard T2W MRI 
in recognizing viable tumour remnants in areas of radiation induced fibrosis. 
For this purpose, quantitative assessment by means of volumetric measurements and apparent 
diffusion co-efficient (ADC) measurements were looked at, and the performance of DWI was 
compared with standard T2- weighted MR images, using the histopathological tumour 
regression grade as the gold standard.  
Secondly, there is recent interest in assessing tumour regression grade on MRI. Hence, the 
performance of TRG assessed using T2W MRI and DWI was also correlated with the 
histopathological TRG. 
 
 
10 
 
AIM 
To assess the role of Diffusion Weighted Imaging in prediction of response to neoadjuvant 
chemoradiation in patients with locally advanced carcinoma rectum  
 
OBJECTIVES 
a) To identify the role of different parameters in diffusion weighted imaging in predicting response to 
neoadjuvant chemoradiation in patients with locally advanced carcinoma rectum, in comparison with 
histopathological tumour regression grade. The variables studied will include 
- Tumour volume pre- chemoradiation, using DWI Volumetry 
- Tumour volume post- chemoradiation, using DWI Volumetry 
- Percentage reduction in tumour volume following chemoradiation (TVRR) 
- ADC value of tumour pre- chemoradiation 
- ADC value of tumour post- chemoradiation 
- Change in the ADC value (∆ADC) and tumour ADC increase rate (TAIR) 
 
b) To compare the performance of DWI with that of conventional T2W MRI in the prediction of 
response to chemoradiation. 
c) To study the comparability between MR tumour regression grade separately assessed with T2W 
HR and DWI with histopathological tumour regression grade 
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REVIEW OF LITERATURE  
 
CARCINOMA RECTUM AND NORMAL RECTAL ANATOMY 
The rectum is a long tubular organ extending from the restosigmoid junction to the anal 
canal. It measures approximately 15 cm in length. The rectum can be divided into three 
segments for describing the location of the lesions. The lower one-third corresponds to the 
first 7-10cm from the anal verge, the next 4-5cm constitutes the mid-third and the last 4-5cm 
forms the upper –third of the rectum.(2) 
 
The lower limit of the rectum is formed by the levator ani muscle/puborectalis sling where it 
inserts into the rectal muscular layer. The rectum is surround By fatty tissue termed as the 
mesorectum which contains lymph nodes, vessels and fibrous septae. The mesorectal fascia 
forms a thin covering over the mesorectum. 
 
The rectal wall is made up of three different layers – the mucosa, submucosa and muscularis 
propria followed by a serosal covering. 
 
THE GLOBAL SCENARIO 
Rectal cancer is one the most common cancers of the GI tract, having a high disease related 
mortality. The incidence of rectal cancer is more than that of the other colonic cancers. 
Among the colorectal cancers, one third occur in the rectum(3). Colorectal cancers account 
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for around 400,000 deaths per year worldwide. Of the 5.2 million deaths/year due to various 
cancers, 55% occur in developing countries.(4) 
 
THE INDIAN SCENARIO 
The incidence of rectal cancer in India is 4-5/lakh population (4). Despite the low incidence, 
absolute number of cases in India is high due to the large population. Due to delay in 
diagnosis and referral from peripheral parts of the country, majority of the cases present in a 
locally advanced stage.(6) 
There is a slight male predilection and increase in incidence beyond 50 years of age. The 
other observation that has been made is the increasing occurrence in young adults. This was 
particularly evident in the Indian series where the number of young patients was relatively 
higher. The incidence rates in urban individuals is observed to be higher and is almost twice 
that of the rural incidence rates.(7)(8) 
 
There are various risk factors known to be associated with rectal carcinomas. Among these 
are; adenomas, dietary and environmental factors, inflammatory bowel disease.(9) The 
adverse factors incriminated being obesity, physical inactivity, consumption of red meat and 
genetic susceptibility. On the other hand, dietary fibres, fruits, polyunsaturated fatty acids 
from fish and phytochemicals are probably protective.(9,10) 
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Histologically, adenocarcinoma accounts for most of the cases (98%). The other types 
encountered are rectal carcinoid (0.1 %), lymphoma (1.3 %), GIST (<1%) and an occasional 
melanoma.(2) 
 
The mortality rate from rectal cancer over the past decade has significantly reduced when 
compared to the statistics before 1995. This has been shown to be due to the neoadjuvant 
therapy and a novel surgical technique called total mesorectal excision (TME)(3,11). 
 
Downstaging of tumour with neoadjuvant concurrent chemoradiotherapy , followed by 
surgery has significantly reduced tumour recurrence rate and improved disease free survival 
in patients with carcinoma rectum.(11)  
The current indications for neoadjuvant chemo-radiotherapy are locally advanced rectal 
cancers (T3,T4 disease), tumours close to the mesorectal fascia(<3mm) and nodal 
involvement. Post-operative adjuvant radio/chemotherapy is given if the CRM on 
histopathology is <2mm and for perforation of tumour during the operative procedure. 
Concomitant chemotherapy and radiotherapy is given over 25 days in 2Gy fractions.(13) 
 
A complete pathological response with no evidence of residual tumour may be seen in as 
many as 38% of patients (13). However it has been noticed that there is a significant 
individual variation of response to preoperative CRT; 9%-25% of patients show complete 
response, 54%-75% show tumour downstaging and the others would show no response. 
Hence, early assessment of response would be highly beneficial, so that treatment can be 
intensified for those patients who may not show a response.(14) 
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Traditional surgery consisted of resection of tumour with a margin of surrounding peri-rectal fat. This 
method had a high recurrence rate of around 40%.The present surgical treatment for locally advanced 
disease is total mesorectal excision (TME) wherein the entire rectum and  mesorectal fat is excised by 
dissecting along the mesorectal fascia.  
TME has shown to improve disease free survival and reduce recurrence rate when compared 
to conventional surgery (11% vs 40% previously).(15) 
This is now the preferred method for locally advanced tumours, the choice of low anterior 
resection or abdominoperineal excision being made depending on the location of the tumour. 
High and mid rectal growths can be excised using a low anterior resection whereas low rectal 
carcinomas require abdomino-perineal excision followed by a colostomy 
In early cancers (stage T1 and T2) which are confined to the mucosa and submucosa, primary 
surgery or transanal endoscopic microsurgery with full thickness excision of the tumour are 
the options of treatment.  
 
Recently, Habr-Gama et al treated patients with a complete clinical response with observation 
alone (wait and see approach). Compared with the patients who underwent surgery after 
tumour regression, the five-year survival rates and disease free survival were better in this 
subgroup(17). 
 
Though the trend is towards conservative approach in many countries, this recent form of 
treatment is still controversial. The adoption of this approach, makes preoperative assessment 
of tumour regression and identification of complete response very important. 
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IMAGING IN CARCINOMA RECTUM 
 
The primary aim while staging rectal cancer preoperatively is to categorize the patients based 
on the risk of recurrence by accurate staging. This has significant clinical implication in terms 
of treatment planning 
 
Staging should be able to identify(2)  
1) Those patients with extramural disease who will require neoadjuvant chemoradiation 
(locally advanced –T3,T4) 
2) Those patients with no involvement of the anal sphincter/levator ani who will benefit from 
a sphincter sparing surgery 
 
The diagnosis and staging of rectal cancer is largely done using MR imaging worldwide. 
MRI shows greater soft tissue resolution with ability to image in multiple planes. There is 
also no additional risk due to radiation. The high resolution images are particularly useful in 
accurate depiction of rectal anatomy(18). 
T2 weighted high resolution images are commonly used to study the different layers of the 
rectal wall. Three such layers can be distinguished – an inner hyperintense layer representing 
mucosa and submucosa, a middle hypointense layer representing the muscularis externa and 
an outer hyperintense layer depicting the perirectal/mesorectal fat. External to this, the 
mesorectal fascia forms a thin  hypointense covering to the mesorectal fat(2). The 
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mesorectum gradually tapers and merges with the rectal wall at the anorectal junction. There 
is no serosal covering over the rectum. 
The tumoral tissue usually has an intermediate signal intensity and T2 weighted images are 
used to stage the tumour according to the TNM staging. The tumour can be polypoid, plaque 
like or circumferential(18).  
 
MR IMAGING INTERPRETATION 
Interpretation of pelvic MR images is prone to considerable interobserver variability and 
requires a thorough knowledge of the disease process, the parameters determining disease 
severity and the implications of false positive / negative findings(18).  
 
Recently, Brown et al proposed a way to standardise reporting and at the same time provide a 
systematic approach to include all the necessary information. The pneumonic ‘DISTANCE’ 
was used for this purpose(19).  
(a) Distance of the tumour from the anal verge (DIS) (19) 
Rectal cancers are divided into upper, mid and low rectal malignancies based on the distance 
measured from the lower end of the tumour to the anal verge.  The surgical technique and 
also the outcome is dependent on the location of the tumour 
 Upper rectal cancers: The inferior edge of the tumour is more than 10cm from the anal 
verge. This is of importance because the peritoneal reflection lies over the anterior wall of 
the upper rectum. There is hence a risk of involvement by tumour and injury during 
surgery. 
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 Mid rectal cancers: The inferior edge of the tumour lies between 5-10cm from the anal 
verge. Tumours in this site have a more favourable outcome, as the entire segment is 
covered by mesorectum and is away from the peritoneal reflection.  
 Low rectal cancers: The inferior edge of the tumour lies less than 5cm from the anal 
verge. The mesorectum tapers at this level, therefore the risk of involvement of the 
mesorectal fascia is higher. The upper end of the puborectalis muscle is seen at the level 
of the anorectal junction. The low rectal tumours also pose a risk of involvement of the 
internal and external sphincters. 
 
(b) T- Staging of rectal cancer 
 
The T-stage of the tumour indicates the depth of invasion 
 Stage T1 tumours involves the mucosa and submucosa and spares the muscular layer 
of the rectal wall. 
 Stage T2 tumours are characterised by infiltration of the muscular layer. The outer 
border between the muscularis and the mesorectal fat is intact and can be visualised as 
a thin hypointense line. 
 Stage T3 tumours extend beyond the rectal wall and infiltrate the mesorectal fat. On 
imaging, this is identified by the inability to visualise the interface between the 
muscularis and the perirectal fat. The recent American Joint Committee on Cancer 
2010, sub classifies T3 in three subgroups. This is because various studies have 
shown that the depth of extramural spread is an important prognostic factor(20,21). 
o T3a – Tumour extends <1mm beyond the muscularis propria 
o T3b - Tumour extends >1-5 mm beyond the muscularis propria 
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o T3c - Tumour extends > 5-15 mm beyond the muscularis propria 
o T3d - Tumour extends >15 mm beyond the muscularis propria 
 Stage T4 tumours infiltrate the surrounding organs and muscles of the pelvic wall 
o T4a – Tumour penetrates visceral peritoneal surface 
o T4b – Tumour invades other organs or structures 
 
Differentiating  T1 from T2 tumours can be difficult on conventional MRI. However, the 
higher grade tumours where there is infiltration of the mesorectal fat can be accurately 
differentiated.  
The accuracy of MRI in T-staging ranges from 59-95%(22–24). 
 
(c)  A – Assessment of anal complex ( Internal/Extenal sphincter and Puborectal 
muscles) 
This is mainly for low rectal cancers which are associated with higher recurrence rates and 
increased morbidity(26). These tumours are treated by abdominoperineal excision and a 
permanent stoma. 
 
Neoadjuvant CRT in many of these tumours can lead to significant disease regression and 
preservation of sphincters. Such tumours can even be treated with a sphincter sparing surgery 
followed by coloanal anastomosis(26,27). 
 
T2W HR coronal images are most accurate for assessment of the anal complex. Sphincter 
involvement can be excluded if the lower end of the tumour lies above the puborectalis sling. 
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For tumours that extend below this point, the involvement of the muscularis propria (internal 
sphincter), intersphincteric plane and external sphincter should be carefully assessed (19). 
 
 
 (d)  N- Staging of rectal cancer 
 
When it comes to N staging there is considerable variability and a clear consensus has not yet 
been established. MRI has low sensitivity and specificity for the detection of nodal 
metastases with accuracy ranging from 43-85%. This is due to the fact that small lymph 
nodes still have a high prevalence of malignancy – 9% in 1-2mm nodes and 17% in 2-5mm 
nodes. 
 
The various parameters used in nodal staging are the size , morphology and signal intensity. 
Studies have shown that detection based on shape, border and signal intensity is more reliable 
than size criteria alone because more than 50% of the nodes are <5mm in diameter(28,29). 
Some consider any detectable node as possibly malignant while some authors have also 
provided a size criteria ( larger than 5mm / 10mm)(28).  The morphological parameters 
considered to be in favour of malignancy are the presence of indistinct or spiculated nodal 
margins and a mottled heterogeneous appearance (29,30). The use of RES specific ultra-small 
iron based particles (USPIO) has also proven to be helpful. These particles are not taken up 
by the neoplastic cells replacing the lymph nodes and hence the pathological nodes can be 
differentiated. The involved nodes will not demonstrate the signal drop produced by the 
paramagnetic effect of USPIO particles. The use of these particles has a higher specificity of 
~75%, however the sensitivity is the same as morphological parameters(30).  
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N-STAGING: AJCC 2010 7
th
 edition  
N0 No regional lymph nodes 
N1 Metastasis to 1-3 regional lymph nodes 
N1a 
N1b 
N1c 
Metastasis to 1 regional lymph node 
Metastasis to 2-3 regional lymph nodes 
Tumour deposits in the subserosa, nonperitonealized perirectal tissues or 
mesentery without regional nodal metastasis  
 
N2 Metastasis to 4 or more regional lymph nodes 
N2a 
N2b 
Metastasis to 4-6 regional lymph nodes 
Metastasis to 7 or more regional lymph nodes 
Table.1: Nodal staging of rectal cancer adapted from AJCC 7
th
 edition 
 
(e)  C – Circumferential resection margin (CRM) 
 
The other important parameter that needs to be assessed is the circumferential resection 
margin (CRM). This refers to the minimum distance between the tumour and the mesorectal 
fascia at any point along its entire extent. This is the most important parameter is predicting 
disease free survival and recurrence after surgical excision (2,32,33). This parameter becomes 
important especially in T3 tumours aiding in risk stratification and treatment planning. 
A positive CRM is defined as tumour lying within 1mm of the mesorectal fascia. 
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 MRI has been proven to be highly accurate in assessing the CRM and thereby the 
involvement of the mesorectal fascia. According to a study, done by Bees-Tan and others(22) 
- a CRM of 5mm on MRI can predict tumour- mesorectal fascia distance of atleast 1mm on 
histopathology with a high degree of confidence (of around 97%) 
 
Hence, the local recurrence is dependent on the CRM and involvement of mesorectal fascia; 
ie a short tumour –mesorectal fascia distance is the most important parameter predicting 
disease free survival. The T-staging system does not actually differentiate between the T3 
tumours which have a wide CRM and those with a narrow CRM. Both will be classified 
under the same stage. It is therefore of importance to accurately assess the CRM in addition 
to the TNM stage. 
 
There are four different patterns in which the CRM can be involved (20) 
A   –   By suspicious lymph nodes  
B   –   By the main tumour itself  
C   –   By extramural vascular invasion  
D   –   By a tumour deposit in the  mesorectum  
Table.2: Patterns by which CRM can be involved in locally advanced rectal cancer 
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(f)  E – Extramural vascular invasion 
 
Extramural vascular invasion (EMVI) is another important prognostic factor which can 
predict disease free survival, local and distant recurrence(34). it can be seen in 50% of the 
patients (20). High resolution MRI has been shown to help in identifying this parameter 
which was otherwise only available from the post operative surgical specimen(34). 
 
EMVI is identified by the presence of tumour cells within the blood vessels located in the  
mesorectal fat. Features that would suggest EMVI are (20) 
 Presence of tumour signal within a mesorectal vessel 
 Expansion of the vessel 
 Extension of tumour through the vessel wall with disruption of its borders 
 
 
 
 
(g)  M - Staging of rectal cancer 
 
Distant metastasis is classified as follows – AJCC 2010  
 
 
M0 No evidence of distant metastasis 
M1 Distant metastasis is present 
M1a Metastasis to one organ or site (ex liver/lung/non regional node) 
M1b Metastasis to more than one organ/site or peritoneum 
Table.3: M- staging of rectal cancer adapted from AJCC 7
th
 edition 
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PATHOLOGICAL ASSESSMENT OF TUMOUR REGRESSION AFTER 
PREOPERATIVE CHEMORADIOTHERAPY 
 
 
 
Following neoadjuvant chemoradiotherapy the most important pathologically determined 
prognostic factors are CRM, ypT & ypN (T and N stage of the resected specimen) and the 
histological tumour regression grade (36). 
 
It has been shown that the visual assessment of the degree of fibrosis in the pathological 
specimen can be used to categorize tumour regression into grades. This is considered to be an 
important predictor of overall survival and disease free survival (36,37). 
 
The histopathological features of regression were first studied by Mandard et al for 
esophageal carcinoma. The disease regression was quantitatively assessed and a grading 
system was proposed(38). 
 
The surgical specimens were analysed and the cases were divided into two groups – the first 
group did not show any regressive changes. The second group included all cases which 
showed features of regression. These changes were as follows: -Cytoplasmic vacuolation, 
nuclear pyknosis and necrosis within the cancer cells- Stromal fibrosis with or without 
inflammatory infiltration. 
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Based on these findings, tumour regression was classified into 5 tumour regression grades 
 
TUMOUR REGRESSION 
GRADE 
 
CRITERION 
GRADE 1 (Complete 
regression) 
Absence of residual cancer and fibrosis extending 
through the wall 
GRADE 2 Rare residual tumour cells scattered throughout 
 the fibrosis 
GRADE 3 Predominant fibrosis but increase in the 
number of cancer cells 
GRADE 4 Residual cancer cells outgrowing the fibrosis 
GRADE 5 Absence of regressive changes 
Table.4: Mandard’s tumour regression grading system(TRG) 
Their results showed that the tumour regression grades correlated with disease free survival 
(p <0.05) 
The tumour regression grades could be further grouped into two which was clinically relevant  
(TRG 1-3 vs TRG 4-5) and were a significant predictor of patient survival (p <0.001) 
In this study, the authors also described that the tumour regression paralleled regression of 
lymph node metastases. 
A pathological complete response (pCR) has the most favourable outcome with regard to 
both survival and recurrence (39).  
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The TRG has been consistently shown to be an independent prognostic factor which can 
predict long-term outcome following pre-operative chemo/radiotherapy in rectal cancer in 
subsequent studies as well. 
 
Some authors also quote the Dworak tumour response grading system(37). 
Grade 0 - No response 
Grade 1 - Dominant tumour mass with obvious fibrosis and vasculopathy (minimal response) 
Grade 2 - Dominant fibrosis with a few easily identifiable tumour cells or groups (moderate 
response) 
Grade 3 - Fibrotic tissue with a few difficult to find tumour cells with or without mucous material 
(near complete response) 
Grade 4 - No viable tumour cells (complete response) 
 
Braun et al, performed a similar regression grading system for head and neck tumours. They also 
reported a significant correlation between tumour regression grades and patient survival (40).  
Hence tumour regression grading of tumours is useful in prognostication and there is correlation 
between response to neoadjuvant therapy and patient survival. 
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RE-STAGING ON MRI FOR LOCALLY ADVANCED CARCINOMA 
RECTUM (41–43) 
 
Patients with locally advanced rectal cancer in whom there is invasion of the mesorectal fat 
and when the CRM, sphincteric involvement is threatened, undergo neo-adjuvant chemo-
radiotherapy  for downstaging  the disease (ideally T3 disease and beyond). 
 
Pathologically the tumour regression has been traditionally classified as complete response 
(no residual tumour), partial response (downstaging of >50% ) and no response, which was 
done after the surgery. Of late, pre-operative assessment of tumour downstaging is being 
routinely performed using high resolution T2-weigted MRI. 
 
The accuracy of routine T2W HR MRI in predicting tumour stage and response is as 
follows(43) 
 NON IRRADIATED 
RECTAL CANCER 
AFTER 
IRRADIATION 
T STAGE 85% 50% 
N STAGE 75% 65% 
CRM 92-95% 66% 
Table.5: Accuracy of T2W MRI in predicting stage of rectal cancer pre and post-CRT 
* mean values 
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The morphological changes seen after radiotherapy include fibrosis, demoplastic response, 
mucinous change and inflammation.  
These changes can be appreciated on MRI (43). 
- Areas of fibrosis appear as very low signal intensity compared to the intermediate signal 
intensity seen in residual tumour. 
- Desmoplasia or reactive fibrosis is due to stromal collagen deposition and does not 
contain tumour cells. This is seen as low intensity strands radiating from the tumour edge. 
- Mucinous change or colloid response appears as very high signal intensity areas (20, 43).  
This can be interpreted in three different ways.  
 Firstly, non mucinous tumours showing areas of mucinous change on post- CRT scans 
indicate areas of necrosis and cystic transformation.  
 Secondly, mucinous rectal tumours can demonstrate residual mucin components with no 
or minimal intermediate signal areas within. This represents acellular mucin and does not 
contain viable tumour within.  
 In the third scenario, there are the mucinous tumous showing non-response. These 
tumours are of high signal intensity with intermediate signal components which are 
unchanged from the baseline. 
 
During evaluation for re-staging, the same parameters and diagnostic clues described 
previously (goes by the pneumonic DISTANCE) are used (20). Both the pre and post – 
CCRT images should be looked at and compared for changes in tumour bulk, extent and 
signal intensity. The T-staging categories are same as those used in the baseline assessment 
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The CRM is also again assessed. The CRM is considered to be infiltrated if the minimum 
distance between the tumoral edge and the mesorectal fascia is less than or equal to 1mm. 
The accuracy of MRI in this regard is however low, because it is difficult to differentiate a 
fibrotic scar adjacent to the mesorectal fascia from viable tumour (20). 
 
The mesorectal and perivascular lymph nodes are assessed with criteria similar to that in the 
pre-CCRT MRI.  
The other important parameters to be identified are invasion of puborectalis muscle, anal 
sphincter, prostate/seminal vesicles and uterus/vagina. 
The majority of imaging assessment is done on T2W high resolution scans 
 
After the MERCURY (Magnetic Resonance Imaging in Rectal Cancer European Equivalence 
Study) trial, a tumour regression grading system on MRI was proposed (4).  This again has 
shown to be a strong indication of tumour recurrence and final outcome of disease. 
The grading system reflected the histopathological method of tumour regression grading. In 
this, the tumour is assessed for the presence of fibrous signal intensity (markedly 
hypointense) and tumour signal intensity.  
The high resolution images are compared with the baseline scan . 
 
The authors concluded that assessment of TRG and CRM on MRI are important markers 
predicting survival outcome. 
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TUMOUR REGRESSION 
GRADE 
 
CRITERION 
1 Predominant fibrosis with no residual tumour 
2 Predominant fibrosis with minimal residual tumour signal 
3 Predominant fibrosis with substantial residual tumour 
signal 
4 Predominant tumour signal  fibrosis with minimal 
fibrosis 
5 Tumour unchanged from baseline 
Table.6: MR tumour regression grading system 
 
SCHEMATIC REPRESENTATION 
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Fig.1a 
TRG 1 – No residual tumour signal 
Fig.1b                  Pre CRT                                                               Post CRT 
TRG 2 – Scanty residual tumour signal 
Fig. 1c                   Pre CRT                                                              Post CRT 
TRG 3 – Residual tumour not exceeding fibrosis 
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Fig.1d                  Pre CRT                                                             Post CRT 
TRG 4 – Tumour with minimal fibrosis 
 
 Fig. 1e     
TRG 5 – Tumour unchanged from baseline 
 
Fig.1(a-e): Tumour regression grade based on MRI T2w imaging. The first image 
corresponds to the pre-CRT MRI while the second image shows the post CRT MRI. a-e 
depict grades 1-5 respectively 
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However re-staging in an irradiated rectum is prone for error and there are many examples 
quoted in literature for both overstaging and understaging. 
 
Overstaging is mainly due to the presence of hypointense soft tissue in the region of the 
tumour. This can be related to fibrosis or desmoplastic reaction due to peritumoral infiltration 
by inflammatory cells. The presence of radiation proctitis and related ulceration also leads to 
misinterpretation as residual disease. T1 and T2 disease is mainly prone for overstaging 
(43,20). 
 
Understaging is due to the difficulty in visualising small residual tumour in a background of 
fibrosis and radiation related changes in the rectal mucosa. 
 
In conclusion, the parameters are to be assessed while restaging rectal cancer are (42) 
1.  Appearance of the tumour, presence of necrotic  and mucinous components                     2.  
Distance from the anal verge                                                                                                           
3.  Length of the residual tumor compared to the baseline and depth of extramural spread       
4.  MRI tumour regression grade                                                                                                          
5.  MRI TNM stage                                                                                                                                    
6. The circumferential resection margin (CRM)                                                                                        
7.  Involvement of the peritoneal reflection 
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RECENT ADVANCES AND METHODS USED IN RE-STAGING RECTAL 
CANCER ON MRI  
 
Recently, MR Volumetry, diffusion and perfusion weighted imaging have been looked at 
for improving diagnostic accuracy in assessing residual disease.  
Dynamic contrast enhanced T1W perfusion studies have been analysed to predict tumour 
behaviour. Increased perfusion within a tumour represents increased microcirculation. This is 
said to reflect angiogenic activity and arterovenous shunting within the tumour, findings 
suggestive of an aggressive tumour (44,45). 
 
MR VOLUMETRY 
MR volumetry  performed on T2W high resolution scans has shown to correlate well with the 
histopathological estimation (46).  
Many studies have looked at the tumour volume reduction rate (TVRR), calculated as a 
percentage by comparing the pre and post CRT studies. The calculation of volume can be 
done either as a semi automated process or by manually tracing the tumour on all sections. A 
three dimension region of interest volumetry has also shown promise in estimating volumes 
(47).  
A regression of the tumour volume by more than 70% is said to be associated with a lesser 
risk of recurrence, better outcome and good tumour regression on histology, with TVRR 
being an independent prognostic parameter(48). 
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A tumour volume reduction of >75% has shown to have a significant association with 
pathological complete response (ypT0 or TRG 1) (49). 
 
Another study by Yeo et al showed that a TVRR significantly correlated with 
histopathological downstaging of the tumour and tumour regression grade. They proposed a 
cut off of >60% for good regression, downstaging and ypT1-2, ypN0 rates.  A TVRR of 
>80% was associated with complete regression (46) . 
MR volumetric studies performed on T2W HR images are quite reproducible even by non 
specialist radiologists. This has shown benefit especially in low rectal growths where 
assessment of the CRM and T-stage is difficult (48). 
 
However, morphologic assessment of post CRT T2W images is difficult due to the presence 
of fibrosis and the inability to accurately determine if there is residual tumour in these regions 
of fibrosis. Also it is often difficult to appreciate scanty intermediate signal due to residual 
disease in areas of extensive fibrosis. (20) 
In view of these disadvantages, MR volumetry frequently over-estimates the tumour volume. 
 
DIFFUSION WEIGHTED IMAGING (DWI) 
Image contrast is provided in diffusion weighted images by utilising the property of random 
motion of water molecules within various tissues (also known as Brownian motion).  In this 
technique, diffusion sensitising gradients are applied around a 180 degree refocusing 
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radiofrequency pulse of a T2 weighted sequence. The corresponding signal loss is measured 
and represented on the Diffusion Weighted images (50). 
The acquisition of diffusion weighted images (DWI) also depends on the strength of the 
diffusion sensitising gradient or diffusion coefficient which is expressed by the b-value. 
Characteristic B values used in pelvic MRI are 0 and 1000 (51). 
 
Using this technique the tissues with relatively stationary water molecules ( ie there is 
restriction of diffusion of particles) appear brighter than those tissues where there is free 
molecular movement. Visual inspection of the diffusion weighted images is used in the 
assessment of diffusion properties of tissues. 
 
In addition to diffusion contrast, diffusion images also have an overlying T2 contrast. In 
regions of long T2 this simulates diffusion restriction (T2 shine through effect). This can be 
eliminated by calculating the pure diffusion coefficient. 
The diffusion coefficient is a measure of the strength of diffusion restriction. 
DWI can determine the diffusion coefficient in each voxel. This is called the apparent 
diffusion coefficient (ADC). The ADC map is a pixel-by-pixel display of all diffusion 
coefficients. 
Quantitative analysis can be performed using the ADC maps (apparent diffusion coefficient). 
This is obtained by post processing of the DWI with atleast two different b values 
(monoexponential decay model).  In the ADC map, diffusion restricted areas appear dark 
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corresponding to the bright areas on DWI. ROIs (region of interest) are drawn on the ADC 
map to obtain the ADC value (50). 
 
The ADC map has a combined effect of the water diffusion and capillary perfusion in the 
extracelluar space. The effect of perfusion is most pronounced at low b-values (5-100 
sec/mm2). On the other hand, high b-values (ex 1000 sec/mm2) overcome this effect and 
hence more effectively depict the cellularity of the lesion (52). 
 
Role of DWI in oncology 
Diffusion weighted imaging (DWI) improves tumour detection when used in conjunction 
with standard T2W MRI.  Since DWI is an indicator of cellularity of a lesion , quantitative 
assessment by using ADC values can be used to predict residual tumour, necrotic areas and 
thereby the tumour aggressiveness (14). 
 
Many studies have investigated the use of diffusion weighted imaging in prostate , liver, renal 
and breast imaging (51). There are few studies which have looked at its utility in evaluating 
rectal cancer, more specifically its utility in tumour downstaging (53–59).  
 
Role of DWI in rectal cancer imaging (Re-staging after preoperative chemoradiation) 
It has become important to assess tumour downstaging after preoperative chemo-radiation as 
this depicts the local recurrence and 5 year survival rate (60). A few studies have tried to 
utilize DWI in this respect. 
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It has been postulated that DWI can be used for diagnosis of early radiation induced 
fibrosis and hence prevent overstaging of disease. Delineation of residual tumour might be 
better appreciated on DWI than conventional T2W images (20, 54). 
 
The initial studies on DWI used only visual analysis in conjunction with T2W MR. They did 
not incorporate quantitative assessment criteria. Authors have shown good result on using 
DWI in conjunction with standard T2W MRI for accurate assessment of disease status 
(57,61).  
 
According to Sun et al (6), who primarily looked at the change in ADC values to  
assess the tumour behaviour, significant increases in the tumour ADC occurred in the 
downstaged group. The increase in ADC was believed to be as a result of cellular insult 
resulting in cell death. This indirectly indicates the sensitivity of the tumour to chemo-
radiation. They postulated that an early increase in ADC occurring by 1 week of CCRT could 
be a marker of tumour downstaging after chemo - radiotherapy. They concluded that early 
increase in ADC along with a low pre-treatment ADC value correlated with a good response 
to chemoradiation (14). 
 
A similar observation was also made by Dzik-Juraz et al who noted that the pre-treatment 
ADC in the responder group was significantly lower than those that do not respond (55). 
 
Some studies have however failed to demonstrate any benefit from ADC measurement pre 
and post CCRT (54,62). 
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Further on, a few studies have assessed diagnostic performance of conventional MR 
volumetry vs DWI in the prediction of complete response to CCRT (62). They performed 
volumetric signal intensity measurements. The results revealed that volume analysis on post-
CRT DWI was more accurate than on T2W images for the prediction of complete response. 
The same conclusions were also drawn by few other studies (54,58). 
 
Curvo-Semedo et al also noted that the volumetric measurements performed on post-CRT 
diffusion weighted images correlated well with the volume reduction measurements on T2W 
MR and DWI. They postulated that pre-treatment volume measurements may not be even 
necessary (57).  
 
Overall, despite contradicting reports, DWI seems to be a promising tool for assessing 
response to treatment and deserves further study. 
 
Technical considerations in performing DWI for rectal carcinoma (51,63) 
 
For diffusion weighted imaging, the most widely employed technique is single shot (SS), spin 
echo (SE), echo-planar imaging (EPI) on 3T or 1.5T scanners with phased array coils. This 
has the advantage of high speed and increased signal-to-noise ratio. 
A short TR (of around 1300msec) is used to decrease acquisition time. A TE of around 60-
70msec is used. Three-four acquisitions are generally performed in a 128x192 matrix. 
 
Some form of fat suppression is also required and STIR is most commonly used in body 
imaging to obtain uniform fat suppression.  
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Parallel imaging (GRAPPA –generalised autocalibrating partially parallel acquisition or  
SENSE – sensitivity encoding) is utilised to decrease distortion and ghosting artifacts.  
 
Breath hold vs Free breathing 
Farhood et al performed three different imaging sequences to identify the best sequence for 
abdominal diffusion weighted imaging – breath hold with parallel imaging, breath hold 
without parallel imaging and free breathing techniques with b-values of 50 and 1000. The 
signal-to-noise ratio was significantly higher for breath-hold acquitions. Breath-hold with 
parallel imaging at 3T had a higher image quality and lower artifacts (64). 
 
Optimal b-value  
B-value indicates the degree of diffusion weighting. A higher b-value is desired to obtain 
greater contrast. However, a very high b-value necessitates longer TE and lower signal to 
noise ratio resulting in image distortion. A low b-value on the otherhand (<100 sec/mm2) 
results in contamination of the ADC map by perfusion effect. Hence an optimal b-value 
needs to be determined (51,65). 
DW MR images and ADC maps are most commonly acquired using b-values of 0 and 1000 
sec/mm2 applied in x,y and z directions for pelvic applications(14). 
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While evaluating rectal lesions, to reduce errors in ADC calculation, some authors prefer 
multiple diffusion encoding with b values of 0, 100, 800 and 1000 sec/mm2 (13).  
 
Different b values for use in gynaecological lesions has been studied. Visual scoring using b-
values of 600,800 and 1000 were found to be successful for differentiating benign and 
malignant lesions. It was noted that the optimal b-values for evaluation of pelvic lesions are 
between 600 and 1000 sec/mm2 (66). 
 
Accuracy of ADC value measurement – PACS vs dedicated workstation  
A dedicated workstation is currently considered the reference standard to be used for 
calculating ADC values. 
Traditionally, ADC values are calculated by exporting the diffusion images in a DICOM 
format to a separate offline MR workstation on which ADC maps were generated using three 
b values. 
There are however many disadvantages in using a separate workstation, like increased time, 
disruption of normal work pattern resulting in underutilization of ADC measurements and 
reduced correlation with the rest of the imaging findings.  
 
Studies have shown that there is no statistically significant difference in the ADC value 
measured  from the PACS system and a specialised workstation (67).  
The slight differences noted are presumed to be due to minor variations in the size and shape 
of the ROI placed. 
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MATERIALS AND METHODOLOGY 
STUDY DESIGN: Study of diagnostic test accuracy 
STUDY TYPE: Analytical 
SETTING:  Christian Medical College (CMC) Vellore is a tertiary care centre in northern 
Tamil Nadu. The institution was established in 1900 and is now a 2700 bedded hospital. The 
annual outpatient visits is around 1.9 million with inpatient admissions of ~ 120,000. The 
Department of Radiology in CMC, Vellore was established in 1936. Digitalization of the 
system and introduction of PACS (Picture Archival and Communication System) was done in 
the year 2000. The Department functions independently with around 80 radiologists. The 
radiological investigations routinely performed are radiographs, IVU, barium studies, 
ultrasonography and Doppler studies, mammograms, CT and MRI.   
 
INCLUSION CRITERIA: 
1) All the patients who presented to our Surgery department (Colorectal unit) with  locally 
advanced rectal cancer (T3,T4) – ie clinical stage T3/T4 and any N or M stage 
2) Those of the above who underwent chemo-radiation followed by surgery in our 
institution. 
3) Those of the above who had an pre and post CRT MRI done in our institution prior to 
surgical resection 
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EXCLUSION CRITERIA 
1) Previous CRT for rectal cancer or any other tumour of pelvis  
2) Contraindication to MR imaging 
3) Premature discontinuation of CRT  
4) Delayed (more than 8 months after CRT) or cancelled surgery due disease progression or 
inoperable malignancy 
5) Discontinued MR imaging examinations during therapy  
 
METHODOLOGY 
 
SAMPLING AND CONSENT: 
The prospective study patients were referred to us from the surgical OPD or ward. All patients who 
fulfilled the inclusion criteria were included in the study. No specific sampling strategy was 
employed to enrol patients. The selection of the study population was independent of the results of 
the reference standard (histopathology). Baseline data of the patients was entered into a numbered 
proforma (Appendix 1). Informed written consent was obtained from the patient / patient’s relative 
prior to the re-staging MRI. The consent form along with the Patient Information sheet is attached in 
Appendix 2. 
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TIMING: 
The time period between the initial MRI and surgery would range between 6-8 weeks. The tumour in 
question is likely to significantly change in this period due to the effects of the chemo-radiation. The 
tumour may regress, remain same or progress. The degree of change in tumour characteristics in 
terms of signal intensity in usual MRI sequence and DWI will be assessed to predict TRG. 
 
MAGNETIC RESONANCE IMAGING (MRI) EXAMINATION 
 
a) MRI scanner 
Pre and post operative MRI was performed at our institution in a 3T scanner (PHILIPS 
Achieva). MRI of the entire abdomen was performed at presentation for the initial staging. 
For re-staging following neoadjuvant chemoradiation, an MRI pelvis alone was performed in 
most of the cases. While doing so, an additional T2 SPAIR sequence of the entire abdomen 
was also done.  
b) MRI coils 
3T – SENSE-XL-Torso MRI coils were used 
 
c) MRI protocol – Sequences and Technique 
The MRI ABDOMEN and MRI PELVIS protocols included the following sequences – T2 
coronal and axial; T2 SPAIR axial; T1 axial; T2 HR images – axial, coronal and sagittal; 
DWI with b values 0, 400, 800; ADC map. 
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(A) Localizer scan/Survey (sagittal, coronal and transverse planes) 
 
(B) T2W coronal ( Repetition time TR – 988ms; Echo time TE – 80ms; Flip angle – 900; slice 
thickness 6mm with slice gap 0.6mm; FOV 375mm; matrix 268x220; one acquisition 
scan time ~ 1.30minutes) 
(C) T2W axial (TR – 941ms; TE – 80ms; Flip angle – 900; slice thickness 6mm with slice gap 
0.6mm; FOV – 375mm; matrix 288x189; one acquisition scan time ~2 minutes) 
(D)  T2W SPAIR axial ( TR – 782ms; TE – 70ms; Flip angle – 900; TI – 220ms; slice 
thickness 6mm with slice gap 0.6mm; FOV – 375mm; matrix 268x163; one acquisition 
scan time ~2 minutes) 
(E) T1W axial (TR – 12ms; TE – 2.3ms; Flip angle – 150; slice thickness 6mm with slice gap 
0.6mm; FOV – 380mm; matrix 256x153; one acquisition scan time ~1.37 minutes) 
(F) T2W HR coronal (TR – 3546ms; TE – 80ms; Flip angle – 900; slice thickness 3mm with 
slice gap 0.3mm; FOV – 230mm; matrix 384x377; one acquisition scan time 
~2.43minutes) 
(G)  T2W HR sagittal ( TR – 3500ms; TE – 90ms; Flip angle – 900; slice thickness 3mm with 
slice gap 0.3mm; FOV – 220mm; matrix 352x273; one acquisition scan time ~2.23 
minutes) 
(H) T2W HR axial( TR – 3500ms; TE – 90ms; Flip angle – 900; slice thickness 3mm with 
slice gap 0.3mm; FOV – 230cm; matrix 368x291; one acquisition scan time ~3.19 
minutes)   
(I) Single shot EPI diffusion weighted transverse (Diffusion mode – 3 scan trace; Diffusion 
weightings – 3; b value 1 = 0; b value 2 = 400; b value 3 = 800; Trace weighted images; 
Average ADC maps; EPI factor – 77; TR – 3750ms; TE – 75ms; slice thickness 4mm 
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with slice gap 0.4mm; FOV – 380mm; matrix 128x116; one acquisition scan time ~3.15 
minutes)  
 
d) Image Interpretation 
The imaging results was viewed and interpreted by the principal investigator with the help of two co-
investigators with experience in pelvic MR imaging. The observers were blinded to patient’s clinical 
data and pathology reports. The data was recorded on the proforma (Appendix 1) 
The index test which is diffusion weighted imaging (DWI) was installed into the protocol for pelvic 
imaging.  
1) For volumetric evaluation, the tumour outline was manually traced on each section. The tumour 
volume was calculated by summing all of the cross sectional volumes of the entire lesion. (Fig.3) 
For those tumours which were circumferential, the lumen of the rectum was included in the 
calculated volume to maintain uniformity among the observers. (Fig.4) 
On volumetry based on T2w scans, the hypointense areas after neoadjuvant therapy were also 
included in the measured tumour volume. This was due to the initial hypothesis stating difficulty 
in differentiating tumour tissue from fibrosis and the possibility of presence of viable tumour cells 
in regions of fibrosis.  
 
2) The analysis of ADC is an automated process which is displayed as a parametric map. ADC 
measurements of a given region were recorded by drawing regions of interest (ROI) on the ADC 
map (Fig.2). The ADC values were initially measuring on the MRI workstation kept at the 
console and also at the PACS workstation. Paired sample T-test showed that:  
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  There is strong agreement between pre treatment ADC values measured in the MRI workstation 
and PACS workstation (r=0.959, p<0.0001). The values measured in PACS is 0.03+/-0.09 x 10
-
3
 less than that measured on MRI WS and the difference is statistically significant (t=3.094, 
df=68, p=0.003). Though there is statistically significant difference between the two values the 
difference is too small to be clinically significant. 
   There is strong agreement between post treatment ADC values measured in the MRI workstation 
and PACS workstation (r=0.91, p<0.0001). The difference between the mean ADC value 
measured in the MRI workstation and PACS workstation is not significant (t=1.043, df=19, 
p=0.310). 
Hence, the subsequent ADC values were measured in the PACS workstation only.  
The DWI Volumetry and ADC values were performed at a different time from the volumetry based 
on T2W MRI to eliminate bias. The results of the reference standard were not available at the time of 
interpretation of the index test.      
In case of studies which did not show any areas of restricted diffusion after neoadjuvant therapy (ie 
complete response), the ROI’s were placed in regions that showed residual tumour on T2w images.                                                                                                                         
3) The tumour regression grades (TRG) on T2w high resolution scans was assigned using standard 
criteria. 
 
Fig.2a: DWI showing restricted diffusion 
within the lesion. 
Fig.2b: Corresponding ADC map with the ROI 
placed within the tumour. 
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Fig.3b: Tumour volumetry as performed on 
DWI (b = 800) 
Fig.3a: Tumour volumetry as performed on 
T2-weighted HR axial scans 
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4) The tumour regression grades (TRG) on DWI were also assigned using the following criteria, 
adapted from RSNA based guidelines on appearances of various tissues on DWI (68).  
 
 
TUMOUR 
REGRESSION GRADE 
 
CRITERION 
1 No residual diffusion restricted areas 
2 A few scattered lakes of diffusion restricted areas 
3 Predominant fibrosis (75%) with substantial diffusion restricted areas 
4 Predominant restricted diffusion with minimal fibrosis 
5 Tumour unchanged from baseline 
Table.7: Tumour regression grading system based on DWI 
Fig.4: Tumour volumetry showing inclusion of 
the lumen in circumferential tumours 
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e) Histopathological Examination:  
 
Histopathology was the standard of reference (gold standard). The slides were reviewed by two 
experienced pathologists with special interest in gastrointestinal pathology. Sections were checked 
for the presence of normal tissue, viable tumour, fibrosis, edema and any other relevant findings.  
The tumour regression grade (TRG) was evaluated according to the method of Mandard et al. (38) 
In addition, the following information was also provided 
 the type of tumour 
 circumferential resection margin 
 vascular and perineural invasion 
 involvement of resected lymph nodes 
 pathological TNM stage (ypTNM) 
 Description of the gross appearance of the main specimen included measurement and 
documentation of the following: Dimensions of the entire specimen, Location, dimensions 
and gross appearance of the tumour and distance of the tumour from the various resection 
margins 
 
 
 
 
 
 
 
 
50 
 
DEPICTION OF THE MANDARD’S TUMOUR REGRESSION GRADES 
 
  
TRG 1: Absence of residual cancer and fibrosis extending through the wall (Complete 
regression) 
 
 
TRG 2: Rare residual tumour cells scattered throughout the fibrosis 
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TRG 3: Predominant fibrosis but increase in the number of cancer cells 
 
  
TRG 4: Residual cancer cells outgrowing the fibrosis 
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TRG 5: Absence of regressive changes  
 
INSTITUTIONAL REVIEW BOARD APPROVAL AND FUNDING :  
Institutional review board (IRB) approval was obtained prior to the commencement of the 
study (IRB minutes number.7657 dated 18.11.2011) (Appendix 3). 
 
STATISTICAL ANALYSIS: 
Statistical analyses were performed using SPSS software version 16. The changes in tumour 
ADC and volumes of the responder and nonresponder groups were analyzed using Wilcoxon 
ranksum/ Mann Whitney test.  
Receiver operating characteristic (ROC) curves were employed to compare the diagnostic 
performance of tumour volume reduction rate and change in the ADC value for the prediction 
of complete response. 
P < 0.05 was considered statistically significant. 
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ANALYSIS AND RESULTS 
 
Flow chart of the progress through phases of study 
 
 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
  
Total number of MRIs requested by 
Department of Surgery (colorectal unit) 
January 2012 to July 2013 = 292 
Number of patients who were in the 
exclusion criteria =1  
Number of patients who were 
operable and consented for 
surgery = 71 
Number of patients who were 
inoperable/ lost to follow up = 23 
Number of patients among these who had 
LCCRT followed by restaging MRI for LARC 
during the study period = 94 
Excluded  
Excluded  
   STUDY GROUP = 70 
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(A) STUDY DESIGN 
Duration of study  
 The study cases were prospectively recruited over a period of 20 months, from December 
2011 to July 2013. 
 
Sample size  
          A total of 292 patients with a clinical diagnosis of rectal cancer were referred from the 
Surgical department (Colorectal Unit) for MRI.  Among these patients 93 came for restaging 
MRI of the pelvis following long course chemo-radiotherapy. Of these patients, 71 were 
operated. There others were either inoperable and were referred for palliative treatment or 
refused surgery or were lost to follow up. 
1 out of the 71 patients was excluded because, the patient had MRI after excision of the 
malignant polyp and there was no significant abnormality in the initial MRI itself. 
Hence, the total sample size was 70. 
 
(B)  PATIENT DEMOGRAPHICS 
 
(i) Age Distribution 
The mean age of the patient population was 49.24 years (range 23-74 years)  
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(ii) Sex Distribution 
Of the 70 patients, 52 were male (74.3%) and 18 were female (25.7%). 
 
(C)  TUMOUR CHARACTERISTICS 
 
(i) Tumour location 
The majority of tumours were low rectal growths, comprising 64.3 % (45 in number). 
27.1% were mid rectal tumours and 8.6% were upper rectal tumours (Fig.5). 
 
(ii) Type of tumour  
The most common tumour type was moderately differentiated adenocarcinoma comprising 
72.9% (51 in number). 
The other histological types were 
- 12.9% mucinous and signet ring cell type 
- 7.1% poorly differentiated adenocarcinoma 
- 2.9% well differentiated adenocarcinoma 
- Others : Squamous cell carcinoma, neuroendocrine tumour and high grade dysplasia. (1.4% 
in each type)        
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CLASSIFICATION OF TUMOURS BASED ON LOCATION 
 
 
 
Fig.5a                                                          Fig.5b 
 
 
 
 
 
 
Fig. 5c 
 
 
 
 
 
 
 
 
Classification of rectal tumours based on their location. Fig.5a depicts a low rectal growth 
Fig.5b depicts an upper rectal tumour and Fig. 5c depicts a mid rectal tumour 
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(iii) Signal intensity of tumour 
 
 
Most of the tumours had intermediate signal intensity on T2W images, accounting for 67.1% 
of the cases (47 in number). (Fig.6) 
A significant number of lesions (15.7%) were hyperintense, suggestive of mucinous tumours. 
The remaining 17% had a mixed signal intensity containing both intermediate and 
hyperintense signal areas. 
 
 
CLASSIFICATION OF TUMOURS BASED ON SIGNAL INTENSITY ON T2W 
IMAGES 
 
 
Fig. 6a 
 
Fig. 6b 
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Fig. 6c 
 
 
(D) TREATMENT STRATEGY 
 
 
D. TREATMENT ADMINISTERED 
 
(i) Neoadjuvant therapy 
 
All patients underwent neoadjuvant chemoradiotherapy (CRT) 
Among these, a large subset of 66 patients (94.3%) was administered long course 
chemoradiation (LCCRT). 
Three patients (4.3%) were given short course CRT due to associated co-morbidities. One 
patient (1.4%) received radical chemoradiation. 
 
The LCCRT regime was given using a four field box with cobalt 60 gamma rays. ~5040cGy 
was administered in 28 fractions along with concurrent chemotherapy with Tab Capecitabine 
(at a dose of 825 mg/sq.m twice a day) 
Classification of rectal tumours based on their signal intensity. Fig.6a depicts an intermediate 
signal intensity rectal tumour. Fig.6b depicts a hyperintense rectal tumour and Fig. 6c depicts a 
mixed signal intensity rectal tumour 
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(ii) Surgery 
 
Nearly equal number of adbomino-perineal excisions (APE) and low anterior resections 
(LAR) were performed, in 47.1% and 52.9% of the study population respectively. 
 
(iii) Adjuvant therapy 
 
91.4% of the patients were given adjuvant chemoradiotherapy. 
The adjuvant treatment comprised various combinations of the following chemotherapeutic 
agents – 5-Fluorouracil, leukovorin, Oxaliplatin, Carboplatin, Etoposide, Capecitabine, 
FOLFOX regime and CAPOX regime. 
 
The six patients who did not have adjuvant treatment were either lost on follow up or 
succumbed to the illness. 
 
 
E. HISTOPATHOLOGICAL EVALUATION 
 
 (i) Distribution of pathologic regression after CRT 
 
 
There were 13 patients (18.6%) who showed complete response to neoadjuvant treatment. 
 
When the five categories are re-grouped into responders (TRG1 and 2) and non-responders 
(TRG 3-5), the percent in each group are 40% (n=28) and 60% (n=42) respectively. 
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The tumours were classified based on Mandard’s tumour regression grading system 
 
TUMOUR REGRESSION 
GRADE 
FREQUENCY PERCENT 
1 13 18.6 
2 15 21.4 
3 21 30.0 
4 18 25.7 
5 3 4.3 
 
Table.8: Frequency distribution of the study group based on the Mandard’s tumour regression grading 
system into 5 categories 
 
 
 
(ii) Circumferential resection margin (CRM) 
 
 
The surgical specimen showed involvement of the CRM in 27.1%, while 72.9% had a 
negative CRM after surgery – defined as tumour to resection margin distance of >1mm. 
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F. MRI EVALUATION 
 
The mean interval between MRI and Surgery was 11.8 days (SD 19.6) 
 
(i) Distribution of pre – CRT stage on MRI (based on TNM classification) 
 
Most of the patients had stage IIIb disease during initial presentation, comprising 74.3% of 
the study population. The TNM categories included in this stage are : 
 
STAGE IIIb T3-T4a N1 M0 
 T2-T3 N2a M0 
 T1-T2 N2b M0 
 
The other disease stages included Stage IIIc (11.4%), Stage IVa (7.1%), Stage IVb (4.3%) 
and Stage IIa (2.9%) 
 
 
(ii) Distribution of post – CRT stage on MRI 
 
 
Most patients continued to remain stage IIIb after neoadjuvant therapy; however the 
percentage had reduced considerably to 42.9%. 
 
The tumour had responded variably and the stages fell into a wide category – Stage IIa 
(24.3%), Stage IIIa (12.9%), Stage IVb (5.7%), Stages I, IIIC and IVa (4.3% each), Stage IIc 
(1.4%). 
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(iii) Distribution of pre – CRT Circumferential resection margin on MRI 
 
 
77.1 % (54 patients) had a positive CRM during the initial staging MRI.  In the remaining 
22.9%, the CRM was not involved. 
 
 
(iv) Distribution of post – CRT Circumferential resection margin on MRI 
 
 
In the post neoadjuvant therapy re-staging MRI, the number of patients with an involved 
CRM had reduced to 61.4 % (43 patients). 
In 38.6% of cases, the CRM was not involved. 
 
 
 
(v) Comparison between CRM determined on MRI and histopathology 
 
 
There was good correlation between MRI and histopathology in determining involvement of 
CRM with a sensitivity of 89.4% (Pearson Chi - square value 8.657, df =1 and p value = 
0.003). 
 
However, when the CRM was negative, the performance of MRI was equivocal 
There was fair correlation between the absolute measured value of CRM on T2W MRI and  
histopathology ( R value 0.463, t = -4.5 and df =52) 
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G. TUMOUR VOLUME ANALYSIS 
 
The median tumour volumes and their range in each pathological category of tumour 
regression grade is summarised in Table.9 and depicted in Fig.7 
 
VOLUME 
mm3 
TRG 1 TRG 2 TRG 3 TRG 4 TRG 5 
Pre CRT –T2W 24  (7.7-61) 26  (8-97) 35  (9-122) 50  (6-134) 39 (25.9-49) 
Post CRT – 
T2W 
4.5 (2.8-8) 7.3  (1-93) 8.7 (1-85) 19 (10-55)* 18 (5-26) 
TVRR T2W 81%  (2-84) 57% (4-95) 71%  (31-88)* 
 
49%  (9-59)* 54% (46-81) 
Pre CRT –DWI 21.5 (5.5-54) 21 (6-98) 21  (9-62) 28  (6-102) 39  (30.7-56) 
Post CRT –
DWI 
0 (0-3) 2 (0-90) 5  (1-33) 8  (1.5-88) 6  (5.5-31) 
TVRR DWI 100 % (76-
100) 
75.7 % (±32) 80  (45-97) 56%  (21-77)* 82% (45-84) 
Table.9                                                                                                         * Interquartile range 
 
 
 
Fig.7a: Box and whisker plot of DW MR tumour volume change rate (TVRR) between the 
different TRG categories. 
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Fig.7b: Box and whisker plot of T2W MR tumour volume change rate (TVRR) between the 
different TRG categories. 
 
 
 
 
For further analysis the patients were stratified into two groups based on the pathological 
TRG – the complete response group (CR) and non-complete response groups (non-CR). 
 
The initial tumour volume measured on T2-weighted MR images was not significantly 
different between the CR and non CR group, measuring 24 mm
3
 (range 7.7-61) and 37 (6-
134) mm
3
 respectively (p=0.06).  
After CRT, the tumour volume had reduced to 4.5mm
3
(range 2.8-8) and 10 mm
3
 (0-99) in the 
two groups (p = 0.002).  
 
On DWI based MR Volumetry, the initial median tumour volume was not significantly 
different between the CR and non-CR groups, measuring 21.5 mm
3
 (5.5-54) and 28.8 mm
3
 
(6-102) respectively (p=0.19).  
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On restaging after CRT, the median tumour volume had reduced to 0mm
3
 (0-3) and 5mm
3
(2-
9.9)* in the CR and non-CR groups, respectively (p<0.001).  
 
 
The post-CRT tumour volumes revealed a significant difference between the CR and non-CR 
in both T2-weighted and DW MR images (P<0.01). 
 
The median reduction rate of tumour volume (TVRR) on DWI was 100% in the CR group 
and 77 % in the non-CR group (P < 0.001).  
The median reduction rate of tumour volume (TVRR) on T2W MR images was 81% in the 
CR group and 58% in the non-CR group (P= 0.02) 
Depiction of the range of values of the TVRR on T2 and DWI is as shown in Fig.8 
 
 
Fig 8a:  Box and whisker plot of T2-weighted MR tumour volume change rate (TVRR) between the 
CR and non-CR groups (P = 0.02). 
The box shows the range from the 25th percentile at the lower edge to the 75th percentile at the upper 
edge. The line across the box represents the median value. The whisker depicts the 10th and 90th 
percentile values.  
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Fig.8b:  Box and whisker plot of diffusion-weighted (DWI) MR tumour volume change rate (TVRR) 
between the CR and non-CR groups (P <0.001) 
 
 
Further to increase the sensitivity, regrouping was done in a different manner – responders 
(comprising TRG 1&2) and non-responders (TRG 3-5) 
In the subsequent analysis the parameters in tumour volumetry showing a significant 
difference between the responders and non responders was reduction rate of tumour volume 
(TVRR) on DWI. The median value was 96% in the responders and 73% in the non 
responders. (p < 0.001) 
The post-CRT volumes on T2 and DWI also showed significant difference between the two 
groups (p<0.01). 
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H. ANALYSIS OF TUMOUR ADC 
 
 
The mean ADC of the tumours in different TRG categories is as depicted in Table.10 and 
Fig.9 
 
 
 
 
ADC (×10
−3
 
mm
2
/s) (mean ± 
SD)  
TRG 1 TRG 2 TRG 3 TRG 4 TRG 5 
Pre CRT 0.936 
(±0.24) 
1.14 (±0.374) 0.854 (±0.118) 1.104(±0.429) 0.940 (±0.157) 
Post CRT  1.49 (±0.2) 1.485(±309) 1.359 (±0.317) 1.378 (±0.387) 1.415 (±0.478) 
TAIR 37% (±14) 23.25% (±18) 34.7% (±13.7) 21.24% (±9.8) 27% (±29) 
Absolute 
increase in 
ADC 
0.554 
(±0.25) 
0.344 (±0.28) 0.505 (±0.28) 0.272 (±0.12) 0.475 (±0.61) 
 
Table.10: Mean ADC values - pre-CRT, post-CRT, Tumour ADC increase rate (TAIR) and absolute 
increase in ADC value (∆ADC) noted in the five TRG groups  
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Fig.9: Box and whisker plot of Tumour ADC increase rate (TAIR) between the different 
TRG categories 
 
 
 
 
For further analysis the patients were stratified into two groups based on the pathological 
TRG – the complete response group (CR) and non-complete response groups (non-CR). 
 
- The mean pre-CRT ADC for the CR group (0.936±0.24× 10
−3
 mm
2
/s) versus the non-CR 
group(1.011±0.33 × 10
−3
 mm
2
/s) showed no statistically significant difference (p = 0.49).  
- Similarly the mean post-CRT ADC for the CR group (1.49±0.2× 10
−3
 mm
2
/s) versus the 
non-CR group(1.4±0.34× 10
−3
 mm
2
/s) also did not show statistically significant difference (p 
= 0.114) 
 
However, the mean rate of ADC increase (TAIR-tumour ADC increase rate) between the CR 
group (37%) versus the non-CR groups (27.1%) showed a significant difference (z= -2.149, p 
= 0.03). 
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The absolute increase in ADC values were also different for the CR group (0.554±0.25× 10
−3
 
mm
2
/s) versus the non-CR group (0.39±0.28× 10
−3
 mm
2
/s) (z= -2.286, p = 0.02). 
 
Depiction of the range of change in TAIR (tumour ADC increase rate) and ADC values of the 
CR and non-CR groups are as shown in Fig.10
 
Fig.10a:  Box and whisker plot of  Tumour ADC increase rate (TAIR) between the CR and non-CR 
groups (P = 0.03). 
 
 
Fig.10b:  Box and whisker plot of absolute increase in ADC value (difference) between the CR and 
non-CR groups (P =0.02) 
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I. COMPARISON OF THE DIAGNOSTIC ACCURACY OF DW MR VOLUMETRY, 
T2W MR VOLUMETRY AND ADC VALUES IN PREDICTING COMPLETE 
RESPONSE 
 
ROC curves were used to compare the diagnostic performance of DW MR Volumetry, T2W 
volumetry and ADC values in predicting complete response.  
 
The variables studied were the ones found to be of significance in the above described 
analysis – TVRR on DWI (∆DWI), TVRR on T2W imaging (∆T2W), TAIR and absolute 
difference in ADC (∆ADC). 
 
The area under the curves (AUC) was measured to study the diagnostic accuracy of the tests. 
The corresponding data is shown in Table.11 
  
The volumetry based on DWI (TVRR) had an AUC 0.921 and was superior to that based on 
T2W volumetry (AUC = 0.707). However, ROC curves showed that both the tests were good 
in assessing complete response Fig.11  
For the post-CRT volumetric measurements, the AUC’s were not significant and fell below 
the diagonal 0.5 line. 
 
 
For the ADC measurements, The ROC curves of TAIR (tumour ADC increase rate) and 
absolute increase in ADC value (∆ADC) were obtained. The corresponding AUC were 0.692 
and 0.704 (Fair), depicted in Fig.12 
These values were better than that of the post-CRT ADC measurement alone (AUC 0.641) 
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Fig.11: Comparison of ROC among DW MR volume reduction rate and T2-weighted MR 
volume reduction rate in predicting complete response 
 
 
 Fig.12: ROC curve depicting the diagnostic accuracy of TAIR and ∆ADC in predicting 
complete response  
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Using optimal cut off values sensitivity and specificity of the different variables in predicting 
complete response was derived.  
 
Tumour volume reduction rate on DWI with a cut off value of 94% had a sensitivity of 83.3% 
and specificity of 83.3%. The positive predictive value was 52.6% and negative predictive 
value was 95.7%. 
 
 DWI MR volume 
reduction rate 
(%) 
T2W MR 
volume 
reduction 
rate (%) 
TAIR ∆ADC 
AUC 0.921 0.72 0.692 0.704 
Sensitivity % 83.3 75 53.8 69.2 
Specificity % 83.3 74.5 82.1 71.4 
PPV % 52.6 39.1 41.2 36 
NPV % 95.7 93.2 88.5 90.9 
Optimal cut off 
value 
94% 77% 40% 0.507x10
-3 
mm
2
/s 
P value <0.001 0.017 0.032 0.022 
Table.11: Comparison of the diagnostic accuracy of T2-weighted MR volume reduction rate, 
DW MR volume reduction rate, Tumour ADC increase rate and ∆ADC in predicting 
complete response 
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J. COMPARISON OF TUMOUR REGRESSION GRADES ON MRI (MR-TRG) AND 
DWI (DW-TRG) WITH HISTOPATHOLOGICAL TRG (Based on Mandard’s 
classification) 
 
 
Agreement between the TRG as assessed using T2W MRI (MR TRG) and DWI (DW TRG) 
was determined by the kappa statistic ( k < 0, poor agreement ,k 0-0.2, slight agreement; k 
0.21to 0.40, fair agreement; k 0.41 to 0.60, moderate agreement; k 0.61 to 0.80,substantial 
agreement; and k 0.81 to 1.00, almost perfect agreement) 
P less than .05 were considered significant.  
 
 
 
(a) Agreement between MR TRG and histopathological TRG 
 
 
                        Expected 
Agreement   Agreement     Kappa      Std. Err.         Z      Prob>Z 
----------------------------------------------------------------------------------- 
  76.43%          68.55%          0.2505     0.0694       3.61      0.0002 
 
 
 
(b) Agreement between DW TRG and histopathological TRG 
 
                        Expected 
Agreement   Agreement      Kappa      Std. Err.         Z        Prob>Z 
-------------------------------------------------------------------------------------- 
  74.63%           66.31%          0.2469     0.0787       3.14      0.0009 
 
 
 
There was fair agreement between the two classification systems based on MRI and 
Mandard’s tumour regression grade. Also, both the classification systems performed almost 
equally in stratification into the tumour regression grades. 
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DISCUSSION 
Locally advanced rectal cancer (LARC - T3, T4 lesions) is treated worldwide with primary 
staging using MRI followed by neoadjuvant chemoradiotherapy (CRT) and surgery.  The 
prognostic factor assessing the response to CRT is given by the histopathological tumour 
regression grade (TRG), after surgery. 
Restaging following CRT has hence become very important in planning and prognostication. 
The patients with a favourable response undergo definitive surgery followed by adjuvant 
treatment while those showing disease progression are either given further 
chemotherapy/palliative treatment. Studies have shown that in cases where there is complete 
regression of disease, a wait and see approach may also prove beneficial, thereby avoiding a 
major surgery and probable colostomy. This line of management has however not been 
adopted in our institution and all patients are advised definitive surgery.  
 
Thus, the role of restaging has been emphasised upon.  
In this study, we have looked at the role of diffusion weighted imaging (DWI) is 
assessing response to pre-operative chemoradiotherapy in patients with locally 
advanced rectal cancer. 
 
RATIONALE BEHIND THE STUDY 
 
Standard T2W high resolution MRI is a part of routine work-up to determine the extent of the tumour 
after CRT. However, there is difficulty in recognizing residual tumour in areas of radiation induced 
fibrosis. Also, following chemoradiotherapy, the tumour undergoes morphological changes like 
mucinous response, desmoplasia and fibrosis. It is difficult to visualize residual disease within these 
regions. Fig.13  
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Fig.13a 
 
                        TUMOUR                                                                FIBROSIS 
 
 
 
Fig.13b 
                        TUMOUR                                                DESMOPLASTIC CHANGE 
 
 
 
Fig.13c 
               TUMOUR                              MUCINOUS RESPONSE 
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Therefore, studies have looked at quantitative parameters like volumetry in assessing 
response. 
Because of its promise in cancer imaging, we looked at the potential role of DWI in 
carcinoma rectum. Also, DWI is a noninvasive technique that does not require the use of 
ionizing radiation or contrast agents and can be easily added to any standard MRI protocol. 
 
We have evaluated the diagnostic performance of DWI in predicting tumour response to 
chemotherapy and also compared it with standard T2W MRI. This was done by correlating with the 
pathological tumour regression grade - TRG (Mandard et al. tumour regression grades 1-5). For this, 
the diffusion weighted images obtained were evaluated in two aspects – (1) tumour volume using 
diffusion volumetry and (2) measurement of tumour ADC values. 
 
As a secondary objective, we have also looked at MR tumour regression grade and its agreement with 
the histopathological tumour regression grade. We have also attempted to define a tumour regression 
grade based on DWI characteristics of various tissues (68).  
 
A few studies done have shown DWI to have a higher sensitivity in detection of residual 
tumour, clearance of mesorectal fascia and also in identifying pathological complete 
responders. There has been no study till date which has looked at the role of DWI in 
predicting the tumour grade pre-operatively (TRG 1-5) in rectal cancers. Also there are few 
studies which have looked at quantitative assessment using DWI (ADC and volumetry), have 
shown promising results. 
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DISCUSSION OF RESULTS 
 
 
DWI provides a good depiction of the primary tumour and residual disease/recurrence when 
used qualitatively in conjunction with T2W MRI. (Fig.14 and Fig.15) 
 
 
Fig.14a: T2W HR images showing a low rectal 
circumferential tumour. 
 
  
Fig.14 b,c: Corresponding DWI (b=800) and ADC map showing restricted diffusion within 
the lesion 
 
 
 
 
 
Fig.15a: T2W HR images showing tumour recurrence post operatively 
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Fig.15 b,c: Corresponding DWI (b=800) and ADC map showing restricted diffusion within 
the recurrent lesion 
 
 
 
 
(a) Volumetric analysis using DWI 
 
 
The results of our study show that tumour volume reduction rate (TVRR) performed on DWI 
was the most consistently significant variable in determining response to CRT and fared 
better than TVRR based on T2w imaging.  
We have depicted the range of values in each category of tumour regression grade as box 
plots (Fig.7). To compare the performance of DWI and T2w imaging, the TRG categories 
were subdivided into two groups – complete response (CR) group and non complete response 
(non-CR) group. 
 
 
 
The volumetric variables found to be significantly different between the two groups were  
 TVRR on DWI   (z =  -4.551, p <  0.001) 
 TVRR on T2w  (z =  -2.241, p =   0.025) 
 Post- CRT volume on DWI   (z =   4.731, p < 0.001) 
 Post- CRT volume on T2w   (z =   3.085, p =  0.002) 
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Among these variables, the ROC curves indicated that TVRR based on DWI had a high 
diagnostic performance (AUC 0.92) for the assessment of complete response. The accuracy 
was more than that for TVRR based on T2W imaging (AUC 0.72). 
 
For the post-CRT volumetric measurements on both DWI and T2W MRI, the AUC’s were 
not significant. 
 
 The median volumes estimated on DWI were lower than those on T2W images in the post 
CRT images (5 vs 10 mm
3
 in the non CR group and 0 vs 4.5 in the CR group) while the 
tumour volume reduction rates were higher (77 vs 58% in the non CR group and 100 vs 81 % 
in the CR group).  
 
The probable reason for this could be our assumption that T2W imaging often overestimates 
residual disease by including areas of fibrosis as part of the tumour. Post RT related edema 
also creates a confusing picture in some cases. (Fig.16) 
 
 
  
 
Fig.16a: T2w MRI showing post RT related edema which can mimic disease in certain cases. 
b: Corresponding DWI image 
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Fig.16c: T2W images of the same patient at the site of tumour shows lesion in the right lateral 
wall 
 
 
 
Fig.16d: Corresponding DWI images at the site of tumour 
 
 
 
Our study showed that when 94% was used as a cut-off for TVRR based on DWI, the 
sensitivity and specificity for detecting a complete response were 83.3%. This also showed a 
high negative predictive value of 95.7%. Similarly when, 77% was used as a cut-off for 
TVRR based on T2W imaging, the sensitivity and specificity for detecting a complete 
response were 75% and 74.5% with a NPV of 93.2%. The results indicate that both DWI and 
T2w imaging can be used for ruling out a complete response, i.e. the presence of residual 
disease is well depicted on both, with DWI being more accurate. 
 
 
With the high diagnostic performance of DW MR Volumetry, it can be hypothesized that a 
visual evaluation of whether or not a high signal intensity suggestive of residual tumour is 
remaining will be practical and less time consuming in day to day practice. Fig.17 
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Depiction of complete response 
 
 
Fig.17 a and b: Rectal tumour prior to CRT on T2x and DWI 
 
 
Fig.17 c and d: Post CRT images showing complete response, seen as fibrosis on T2w 
imaging and absence or restricted diffusion on DWI 
 
 
Our results are in concordance with most studies that have shown benefit in performing 
TVRR for assessing disease response(46,49). Further, our study has also shown superiority of 
TVRR based on DWI when compared to T2w imaging (58,59).  
However, we did not find benefit in assessing pre-CRT volumes and post-CRT volumes 
alone in depicting response to treatment. 
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(b) Quantitative assessment using ADC values 
 
 
This parameter was studied under the assumption that post CRT, the tumour shows decrease 
in cellularity and would show an increase in the ADC. 
The pre and post CRT ADC values as well as change in ADC values (absolute increase and 
percentage increase in value) were assessed in the different TRG categories. 
 
Similar to the volumetric analysis, the categories were subdivided into CR and non-CR 
groups. 
The variables found to be significantly different between the two groups were  
 Tumour ADC increase rate (TAIR) ; (z =   -2.149, p = 0.03) 
 Absolute increase in ADC value (∆ADC); (z =   -2.286, p = 0.022) 
There was no significant difference between the groups in the pre-CRT and post-CRT ADC 
values. 
 
On ROC curve analysis of the TAIR and ∆ADC, the area under the curves were 0.692 and 
0.704 which implied fair accuracy in predicting complete response. 
These values were better than that of the post-CRT ADC measurement alone (AUC 0.641) 
Optimal cut off points for these variables were TAIR - 40% and ∆ADC – 0.507x10-3. 
However, the sensitivity (53.8% and 69.2%) was low and specificity (82% and 71.4%) was 
moderate. 
 
Hence, our study has shown beneficial results for change in ADC values (TAIR and ∆ADC); 
the accuracy however being inferior to volumetric assessment of high b value images. 
We did not find pre and post CRT assessment of ADC values useful in predicting response to 
treatment.  This observation was contradictory to few studies which have shown a high post 
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CRT ADC and low pre-CRT ADC value to be helpful in predicting complete 
response(14,69).  
 
 This discrepancy may be related to the fact that a significant component of our study 
population comprised of mucinous/signet ring cell type of adenocarcinoma (~13%). These 
tumours demonstrate T2 shine through effect on DWI and in view of this, the ADC values are 
high both pre and post CRT. These tumours are also known to be resilient to CRT and occur 
in a younger population. Fig.18 
 
 
Fig.18a Mucinous adenocarcinoma appearing hyperintense on T2w axial image 
 
 
 
Fig.18b and c: DWI of the tumour demonstrating T2 shine through effect (facilitated 
diffusion 
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(c) Tumour regression grading on T2W MRI and DWI 
 
 
The MRI tumour regression grade based on T2W imaging showed good agreement with the 
histopathological tumour regression grades. This was in concordance with the MERCURY 
trial(42). Hence TRG can be used as a prognostic indicator for disease recurrence and 
survival. 
 
We had also graded tumour response using DWI using similar criteria based on the 
assumption that residual tumour would show restricted diffusion compared to fibrosis and 
hence the amount of tumour and fibrosis from the baseline scan can be compared (Fig.19). 
This again showed good agreement with histopathological tumour regression grades.  
Thus, the use of DWI in conjunction with T2W HR MRI would help in providing an accurate 
TRG. 
 
 
 
TRG 1 – No residual tumour 
 
 
 
TRG 2 : Scanty lakes of restricted diffusion (viable tumour) 
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TRG 3: Predominant fibrosis with substantial diffusion restricted areas 
 
 
 
 
 
 
 
TRG 4 - Predominant restricted diffusion with minimal fibrosis 
 
 
 
 
 
 
TRG 5 – No change from baseline 
 
 
 
 
 
Fig.19: Tumour regression grades based on diffusion characteristics of tissues.  
The first image in each set shows the pre-CRT appearance and the accompanying image shows the post-
CRT appearance. 
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LIMITATIONS 
This study was subject to few limitations 
1.  Some of the studies had interpretation difficulties due to artifacts and the DWI protocol 
had to be gradually tailored to obtain optimum image clarity. 
2. Since our study had a substantial number of mucinous tumours, the assessment of mean 
ADC may not be accurate. These tumours demonstrate T2 shine through effect rather than 
diffusion restriction. 
3. Another reason for falsely assuming restricted diffusion is when the rectal lumen contains 
fluid, especially layered along the dependent wall. This was carefully interpreted by cross 
referring with the ADC map. 
2.  Some of the patients did not have MRI done according to protocol. Most of these cases 
were done either as an emergency or in the late hours. 
3. The regimes used for CRT were not uniform among all patients. This is probably not 
important because we did not evaluate the efficacy of the treatment regimen but assessed the 
DWI tumour volumetry and ADC change as predictive factors of tumour regression. 
4. A direct correlation between preoperative MR images and surgical specimen was not 
possible as the actual histopathologic tumour volume could not be obtained. This was not 
done due to specimen shrinkage and changes in appearance during transport and storage. 
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CONCLUSIONS 
1. MRI due to its excellent soft tissue resolution and multiplanar imaging capability is an 
established modality to image rectal carcinoma. T2-weighted high resolution scan 
performed perpendicular to the axis of the tumour is the current investigation of choice in 
initial staging. 
2. When it comes to restaging after neoadjuvant chemoradiotherapy, the accuracy of T2W 
imaging is lower due to the inability to confidently distinguish residual tumour from 
fibrosis, desmoplasia and identify viable tumour within mucinous components. 
3. DWI is an emerging modality and is useful in re-staging rectal cancer after neoadjuvant    
chemoradiotherapy prior to surgery. Qualitative as well as quantitative analysis can be 
done. Quantitative parameters include volumetry and ADC values. 
4. Tumour volume reduction rate (TVRR) performed on DWI as well as T2W imaging are 
both useful in assessing complete response. The accuracy of DWI volumetry (AUC 0.92) 
is more than that of T2W volumetry (AUC 0.72). 
5. A cut-off value of 94% for the tumour volume reduction rate on DWI and 77% on T2W 
imaging predicts complete response with high accuracy (AUC 0.833 and 0.748 on DWI 
and T2W respectively). 
Both and these tests also have a high negative predictive value (95.7% and 93.2% on DWI 
and T2W respectively). This would indicate that both DWI and T2W imaging can be used 
for ruling out a complete response, i.e. the presence of residual disease is well depicted on 
both, with DWI being more accurate. 
6. In view of the high diagnostic performance of DW MR Volumetry, it can be hypothesized 
that a visual evaluation of whether or not restricted diffusion suggestive of residual 
tumour is remaining will be practical and less time consuming in day to day practice. 
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7. On ADC analysis, the tumour ADC increase rate (TAIR) and  absolute increase (∆ADC) 
among the CR and non-CR groups though statistically significant as a predictor of 
response was inferior to tumour volumetry on DWI (AUC 0.7 vs 0.92 for ADC and 
volumetry respectively). 
8. Tumour volumes measured either on pre-CRT or post-CRT T2w and DW images were 
not beneficial when used alone for assessment of response.  
9. Pre and post CRT assessment of ADC values were not accurate in predicting response to 
treatment. Unlike other studies, this finding could be due to the high incidence of 
mucinous tumours in our population which do not demonstrate restricted diffusion. 
10. Tumour regression grade (TRG) assessed using T2w MRI as well as DWI are in good 
agreement with histopathological tumour regression grade. 
11. In conclusion, considering the high diagnostic performance of TVRR based on DWI, the 
use of DWI in conjunction with T2W MRI will be useful in assessing response to 
treatment. Tumour regression grade assessed using T2W MRI and DWI can be used as a 
prognostic marker for disease recurrence and overall survival.  
 
In daily practice, T2W high resolution scans could be used as a reference for tumour 
location. DWI in combination with T2W MRI could lead to more accurate detection of 
residual tumour, despite the relatively low spatial resolution and image quality of DWI 
alone. 
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APPENDIX 1 
 
Christian Medical College, Vellore 
Department of Radiodiagnosis 
 
A study on role of diffusion weighted MRI in assessing the response to chemo radiotherapy 
in patients with locally advanced rectal cancer 
 
PROFORMA 
 
 
 
Serial no: 
 
1. Name:                                 2. Sex:                          3. Age:                     4. Hosp no:                               
5. Referring unit 
 
 
 
Clinical information 
 
1. Clinical history and findings: 
 
 Duration of symptoms: 
 
 
 Findings on examination: 
 
 
 Rectoscopy /Sigmoidoscopy findings: 
 
 Colonoscopy findings: 
 
 
2 Pre-CRT stage on 1st MRI ( T2W):  
 
 
3 Biopsy report: 
 
 
4 Type and duration of chemo-radiation: 
 
 
5 Duration between CRT and surgery: 
 
6 Duration between restaging MRI and surgery: 
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7 Type of surgery performed: 
 
 
8 Has the patient discontinued CRT / not undergone surgery (cause): 
 
 
 
3. Histopathology 
 
1 Histopathologic diagnosis  
o Well differentiated adenocarcinoma-1/ moderately differentiated 
adenocarcinoma-2 / poorly differentiated adenocarcinoma -3 / mucinous 
adenocarcinoma -4 / signet ring cell carcinoma -5 
 
 
2 Postoperative histopathologic stage: 
 
 
3 Tumour size (gross specimen): 
 
 
4 Tumour regression grade (1-5): 
 
 
5 Pathological complete response( TRG 1) or incomplete response(TRG2-5) : 
 
 
 
4. MRI 
 
 
1. Pre chemoRT MRI:  
 
Site: 1- low/ 2- mid/ 3- high rectum  
 
 
 
            T2W           DWI 
T Stage   
CRM   
N Stage   
M stage   
Volume of tumour   
ADC value: 1
st
 ROI   
             2
nd
 ROI   
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             3
rd
 ROI   
             Mean   
 
 
 
2 . Post chemoRT MRI:  
 
Site: 1- low/ 2- mid/  3-high rectum  
 
    
             T2W              DWI 
T Stage   
CRM   
N Stage   
M Stage   
Volume of tumour   
ADC value – 1st ROI   
              2
nd
 ROI   
              3
rd
 ROI   
              Mean   
 
Is the result unclear due no remaining high signal intensity tumour tissue : 
 
 
% reduction in volume (T2W): 
 
% reduction in volume (DWI):  
 
Change in ADC: 
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APPENDIX 2 
 
INFORMED CONSENT 
 
 
Department of Radiodiagnosis, Christian Medical College, Vellore 
 
A study on role of diffusion weighted MRI in assessing the response to chemo radiotherapy 
in patients with locally advanced rectal cancer 
 
Information sheet 
 
You are being requested to participate in a study to see if a new MRI technique called 
diffusion weighted imaging (DWI) can help in assessing the response to chemo-radiation 
before you undergo surgery. Presently the response can only be accurately assessed after 
the surgery by microscopic evaluation of the tumour tissue. By preoperative imaging using 
this special technique, we may be able to get an idea about the prognosis of this disease at 
an earlier stage.  
How does DWI help in assessment after chemo-radiotherapy? 
We have observed that there is difficulty in identifying tumor tissue amidst post radiation 
changes using routine MRI scan. However with the help of DWI, the tumour tissue can be 
identified as bright areas and easily differentiated from post radiation changes. However, 
we have only used this for a few people and we need to use it on more people to be sure 
that it really helps. 
Does DWI have any side effects? 
There are no known side-effects. This additional scan will take 2 minutes of the total scan 
time and will be a part of routine MRI. 
If you take part what will you have to do? 
If you agree to participate in this study, there will be no change in the other treatments and 
investigations that you will be having. You will be expected to come for the initial MRI and 
the repeat MRI after chemo radiotherapy as advised by your doctor. No additional blood 
tests will be done as a part of this study. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way.  
What will happen if you develop any study related injury? 
This scan does not involve injections or radiation and it is completely non invasive. So, we do 
expect any procedure related injury. However you can immediately report to us. 
Will you have to pay for the DWI?  
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You will not be charged for this additional scan. All other investigations, as requested by 
your doctor will continue in the usual manner.  
What happens after the study is over? 
You may or may not benefit from this study. Once the study is over, if we come to a 
conclusion that the investigation is beneficial, we will be able to use this sequence in 
assessing and prognosticating patients in future. Your doctor may also use this on you again 
to detect recurrence if required. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission. 
 
100 
 
CONSENT TO TAKE PART IN THIS STUDY 
 
Study Title: A study on role of diffusion weighted MRI in assessing the response to chemo 
radiotherapy in patients with locally advanced rectal cancer 
 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
 
I_________________________________,son/daughter of   
______________________________ 
Declare that I have read/been read to the information sheet provided to me regarding this 
study and have clarified any doubts that I had. [  ] 
 
(Please tick boxes) 
I also understand that my participation in this study is entirely voluntary and that I am free 
to withdraw permission to continue to participate at any time without affecting my usual 
treatment or my legal rights [  ]  
 
I understand that the study staff and institutional ethics committee members will not need 
my permission to look at my health records even if I withdraw from the trial. I agree to this 
access 
 [  ]  
 
I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [  ] 
 
I understand that my identity will not be revealed in any information released to third 
parties or published [  ]   
 
I voluntarily agree to take part in this study [  ] 
 
Name: 
Signature/thumb impression 
Date: 
 
Name of witness: 
Relation to participant: 
Date: 
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APPENDIX 3 
 
ABSTRACT 
 
Objective: To assess the role of DWI in predicting response to neoadjuvant 
chemoradiotherapy in patients with locally advanced carcinoma rectum (LARC) compared 
with T2W imaging. Secondarily, to evaluate the accuracy of tumour regression grade (TRG) 
assessed using MRI (T2W and DWI) in comparison with histopathological TRG. 
Methods: A prospective analysis of 70 patients with LARC, who underwent neoadjuvant 
CRT and subsequent surgery was done. All patients underwent pre- and post-CRT T2W MR 
and DWI. The tumour volumes on T2W and DW images, difference in tumour volumes, pre 
and post-CRT ADC, difference in tumour ADC were measured. The TRG on T2W MRI and 
DWI were independently assessed. Histopathologic tumour regression grade was the standard 
of reference. The diagnostic accuracy of the tests in predicting complete response was 
compared using ROC analysis. The agreement between the MR tumour regression grades and 
histopathology was assessed using kappa statistic. 
Results: The range of volumetric and ADC values in each TRG category were derived. The 
groups were subdivided into complete response (CR, n=13) and non-CR groups. Tumour 
volume reduction rate (TVRR) calculated on DWI and T2W MR were both useful in 
assessing complete response, with the accuracy of DWI being superior (AUC 0.92 for DWI 
vs 0.72 for T2W). The tumour ADC increase rate (TAIR) and absolute increase (∆ADC) 
though statistically significant as a predictor of response was inferior to tumour volumetry on 
DWI (AUC 0.7). Using a cut-off value for the tumour volume reduction rate of more than 
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94% on DWI, the sensitivity and specificity for predicting CR was 83.3% with NPV of 
95.7%.  
There was fair agreement between the TRG based on MRI (76.4%, kappa 0.25, p <0.01) 
/DWI (74.6%, kappa 0.24, p <0.01) and histopathological TRG 
Pre- and post-CRT volumetry, ADC values when viewed independently were not reliable. 
 
Conclusion: The parameters found to be of significance in assessing response to neoadjuvant 
CRT are tumour volume reduction rate - TVRR on DWI and T2W, tumour ADC increase rate 
– TAIR and ∆ADC. Among these, volumetry based on DWI was superior with high 
diagnostic accuracy in predicting complete response. TVRR based on T2W and changes in 
ADC values had similar diagnostic accuracies. 
Tumour regression grade assessed using T2W MRI and DWI are also useful as prognostic 
markers for disease recurrence and overall survival. 
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APPENDIX 4 
DATA SHEET: PAGE 1
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Data sheet: page 2 
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Data sheet: page 3 
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Data sheet: page 1-continued 
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Data sheet: page 2-continued 
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Data sheet: page 3-continued 
 
 
